Avid Bioservices Inc (CDMO)

[Thurly]

All I can say is, it's a bet I'd be very happy to lose. Friday will be interesting if they show encouraging data from the pancreatic cancer trial. It's a full P2 with 70 patients enrolled.

This is prospective, randomized, open-label, multicenter, phase 2 study of gemcitabine with or without bavituximab in patients with previously untreated stage IV pancreatic cancer.

Estimated Enrollment: 70
Study Start Date: January 2011
Estimated Study Completion Date: December 2012
Estimated Primary Completion Date: June 2012 (Final data collection date for primary outcome measure)

Primary Outcome Measures:
Overall survival of patients with stage IV pancreatic cancer treated with gemcitabine alone or gemcitabine with bavituximab.

15 enrolment centres in the USA
4 enrolment centres in the Ukraine